ClinicalTrials.gg
RecruitingNCT07128797Updated Aug 19, 2025

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease(NAFLD)

A Phase 1 interventional study of B1344 and Placebo in NAFLD (Non-alcoholic Fatty Liver Disease) and NASH (Nonalcoholic Steatohepatitis), sponsored by Tasly Biopharmaceuticals Co., Ltd.. Recruiting at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Tasly Biopharmaceuticals Co., Ltd. (part of China Resources Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
81st of 89
32 · median 112
Started
2025
with 10 others
Phase 1
18 of 143
4 open now
Primary completion
2026-06
later than 18 of 52 live
Registered
128th of 143
by date

Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 81st largest by planned enrollment of the 89 interventional ones that give a count, is one of 11 that started in 2025, is one of 18 in phase 1, reaches primary completion later than 18 of the 52 other live ones, and was the 128th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of B1344 in patients with NAFLD. Additionally, the trial will conduct preliminary observations on the efficacy of B1344, aiming to provide early proof of concept for B1344 as a therapeutic agent for NASH.

03

Conditions studied

  • NAFLD (Non-alcoholic Fatty Liver Disease)
  • NASH (Nonalcoholic Steatohepatitis)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese patients aged between 18 and 75 years;
  2. Patients diagnosed with NAFLD and with a magnetic resonance proton density fat fraction (MRI-PDFF) ≥10% in the screening/baseline period or within one month prior;
  3. Presence of any one of the following metabolic risk factors:

    • (BMI) ≥24.0 kg/m² or abdominal obesity (male waist circumference ≥90 cm, female waist circumference ≥85 cm);
    • Fasting blood glucose ≥6.1 mmol/L, or 2-h blood glucose after glucose load ≥7.8 mmol/L, or (HbA1c) ≥5.7%, or history of type 2 diabetes, or Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR) ≥2.5;
    • Resting blood pressure ≥130/85 mmHg, or currently receiving antihypertensive medication;
    • Fasting serum triglycerides (TG) ≥1.70 mmol/L, high-density lipoprotein cholesterol (HDL-c) ≤1.0 mmol/L (male) and 1.3 mmol/L (female), or currently receiving lipid-lowering medication.
  4. Weight stability reported by participants within 6 weeks before enrollment (absolute weight change ≤5%).
  5. Participants have no fertility plans within 3 months after signing the and voluntarily take effective measures.
  6. Voluntary participation in the clinical trial, able to sign the informed consent, and capable of understanding and complying with the trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Liver , or clinical diagnosis of cirrhosis based on clinical presentation, biochemical and imaging results, or any of the following criteria: ① FIB-4 score ≥3.48 in the screening/baseline period or within 1 month prior, or liver stiffness value (LSM) ≥15 kPa based on FibroScan; ② liver biopsy results indicating NASH-F4 stage within the previous 24 months; ③ clinical examination signs of liver cirrhosis or splenomegaly during the screening/baseline period; ④ abdominal imaging results showing liver nodules or splenomegaly during the screening/baseline period or within 1 month prior.
  2. History of tumors or liver transplantation, or patients planning to undergo liver transplantation.
  3. History of liver diseases other than NAFLD or clinical suspicion of liver diseases other than NAFLD, including but not limited to secondary NAFLD, , , hepatitis, hemochromatosis, alcoholic liver disease, primary sclerosing cholangitis, primary biliary cholangitis, or Wilson's disease.
  4. History of other diabetes besides T2DM (such as type 1 diabetes, secondary diabetes, etc.), or currently using or planning to use insulin, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) analog drugs for treatment.
  5. Presence of other severe, progressive, or uncontrolled diseases besides T2DM, hypertension, and dyslipidemia, including but not limited to immune system, endocrine system, hematologic system, urinary system, hepatobiliary system, respiratory system, nervous system, psychiatric system, cardiovascular system, digestive system, where participation in this trial would increase participant risk as determined by the investigator.
  6. Previous history of weight-loss surgery or plans for weight-loss during the trial, or significant changes in exercise or dietary habits.
  7. History of extra-bone injury, fracture, or bone-related surgery within 2 months before screening.
  8. Participants with a history of long syndrome or family history of sudden death, or males with QTcF > 450 ms, females with QTcF > 470 ms.
  9. Allergic to B1344 or its , or history of allergy to other biological products or severe allergic reactions.
  10. History of drug use related to secondary NAFLD lasting more than 2 weeks within 12 months before screening, including amiodarone, methotrexate, systemic , 5-fluorouracil, irinotecan, tetracycline, tamoxifen, doses exceeding hormone replacement estrogen, anabolic steroids, valproic acid, and other known hepatotoxic drugs.
  11. History of concomitant treatment that does not meet protocol requirements before enrollment, or concomitant treatment that meets protocol requirements but cannot maintain a stable dose until the end of the trial, or plans to initiate new concomitant treatments after the first dose until the end of the trial.
  12. Previous use of FGF-21 analogs or FGFR1 agonists.
  13. Screening/baseline examination results meeting the following criteria:

    • (ALT) or aspartate aminotransferase (AST) ≥5 times the (ULN), total >ULN;
    • Estimated (eGFR) \<60 mL/min/1.73m²;
    • \<120 g/L (male) or \<110 g/L (female);
    • ≥9%; fasting blood glucose ≥13.9 mmol/L;
    • (INR) >1.3;
    • count \<110×10⁹/L;
    • Dual-energy X-ray absorptiometry (DXA) T-score ≤-2.5;
    • Resting systolic blood pressure \<90 or ≥160 mmHg, resting diastolic blood pressure \<50 or ≥100 mmHg;
    • Resting heart rate \<60 or >100 beats/minute;
    • TG ≥5.65 mmol/L;
    • Hepatitis B surface antigen (HBsAg) positive, hepatitis C antibody (HCVAb) positive, (HIV) antibody positive, or positive for serum Treponema pallidum specific antibody (TP-Ab).
  14. History of long-term excessive alcohol consumption, or alcohol consumption ≥14 World Health Organization (WHO) alcohol units per week (1 WHO alcohol unit = 10 g pure alcohol) within 3 months before screening, or positive alcohol screening, or unable to refrain from alcohol 48 hours before the first dose until the end of the trial.
  15. Excessive consumption of tea, coffee, or caffeinated beverages (daily consumption of more than 8 cups of respective drinks, with 1 cup being 250 mL) within 3 months before screening, or consumption of any caffeinated food or drink (such as coffee, strong tea, chocolate, cola, etc.) within 48 hours before the first dose.
  16. History of blood donation, loss of blood ≥200 mL, blood transfusion, or use of blood products within 3 months before screening, or plans to donate blood during the trial.
  17. History of needle phobia, blood phobia, or frequent episodes of orthostatic hypotension, or inability to tolerate venipuncture.
  18. History of drug abuse, or positive urine drug abuse screening.
  19. Smoking more than 5 cigarettes daily within the last 3 months or cannot completely quit smoking during the trial.
  20. Women who are pregnant or breastfeeding, or planning to become pregnant or breastfeed during the trial.
  21. Any skin or abdominal wall anomalies that would affect subcutaneous injection, or tattoos or scars covering more than 50% of the abdominal wall surface area.
  22. Participation in other clinical trials and receiving trial interventions within the last 3 months.
  23. Existing MRI examination or inability to cooperate with MRI examinations before screening.
  24. Other circumstances deemed unsuitable for participation in this trial by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    B1344 30mg weekly (QW)

    Drug: B1344

  • Experimental
    B1344 45mg weekly (QW)

    Drug: B1344

  • Experimental
    B1344 60mg Every 2 Weeks (Q2W)

    Drug: B1344

  • Experimental
    B1344 90mg Every 2 Weeks (Q2W)

    Drug: B1344

  • Placebo comparator
    Placebo QW or Q2W

    Other: Placebo

Interventions

  • DrugB1344

    Subcutaneous injection

  • OtherPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Frequency and severity of Adverse Events (AEs) and Serious Adverse Events

    Time frame: 113 days

Secondary outcomes

  1. The maximum observed serum concentration (Cmax) of B1344.

    Time frame: 113 days

  2. Time to peak serum concentration (Tmax) of B1344

    Time frame: 113

  3. Area under the serum concentration versus time curve from time zero to the last measurable concentration (AUClast) of B1344

    Time frame: 113

  4. Terminal elimination half-life (t1/2) of B1344

    Time frame: 113

  5. Compare the changes in triglycerides (TG) after administration compared to the baseline, as well as the percentage changes.

    Time frame: 90 days

  6. Absolute Change From Baseline in Hepatic Fat Fraction Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at day 90.

    Time frame: 90 days

  7. Percent Change From Baseline in Hepatic Fat Fraction Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at day 90.

    Time frame: 90 days

  8. The proportion of participants with ≥30% relative fat reduction on MRI-PDFF compared to the baseline at day 90

    Time frame: 90 days

  9. Absolute Change and Percent Change From Baseline in HbA1c at day 90.

    Time frame: 90 days

  10. The proportion of participants with ≥17U/L reduction on ALT compared to the baseline at day 90.

    Time frame: 90 days

  11. Absolute Change and Percent Change From Baseline in ALT and AST at day 90.

    Time frame: 90 days

  12. Absolute change and percent change from baseline in pro-C3 based on Fibroscan liver stiffness measurement (LSM) at day 90.

    Time frame: 90 days

  13. Absolute Change and Percent Change From Baseline in Body Weight at Day 90.

    Time frame: 90 days

07

Study locations

1 of 5 sites recruiting
  • Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University
    Beijing, Beijing Municipality, China
    Recruiting
    • Lai Wei · Contact
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Jinjun Chen · Contact
    • Chongyuan Xu · Contact
  • Sinopharm Tongmei General Hospital
    Datong, Shanxi, China
    Not yet recruiting
    • Xiujun Li · Contact
  • The First Affiliated Hospital to Nankai University
    Tianjin, Tianjin Municipality, China
    Not yet recruiting
    • Tao Han · Contact
  • The First Affiliated Hospital to Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Not yet recruiting
    • Minghua Zheng · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 11 months after the start.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 11 months is close to that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Aug 19, 2025
StartActual
Jul 24, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jul 2026
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07128797
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Jul 24, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Aug 19, 2025

Study contacts

Lai Wei
Contact
weilai@mail.tsinghua.edu.cn
13601281862

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion